Hepatitis C News and Research

Latest Hepatitis C News and Research

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

Accelerated hepatitis B vaccination schedule effective for high-risk pregnant women

UT Southwestern Medical Center maternal-fetal specialists have confirmed a potential new protocol to protect pregnant women who are at risk for hepatitis B, a health problem that affects 2 billion people worldwide.

28 Jun 2011

Australian Nobel Prize winner closer to delivering vaccines in food after positive first study in humans

The Australian scientist who won a Nobel Prize for identifying a cancer-causing stomach bacterium, today said a clinical trial had shown that some strains of the bacteria (Helicobacter pylori or H. pylori) were safe and well tolerated in humans.

27 Jun 2011

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Dr Seizaburo Kashiwagi presented the preliminary data from an influenza Phase III prophylaxis study conducted during the 2009/2010 pandemic flu season in Japan.

27 Jun 2011

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.

24 Jun 2011

Daewoong, Medivir sign distribution agreement for Xerclear in China and Hong Kong

Medivir AB, a research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has signed an agreement with Daewoong Pharmaceutical Co. Ltd. to exclusively distribute Medivir's unique cold sore treatment Xerclear in China and Hong Kong.

23 Jun 2011

Incivek-combination therapy increases chances of HCV patients achieving viral cure

The drug Incivek, when given in combination with two other medications, can dramatically increase the chances of people chronically infected with untreated genotype 1 hepatitis C virus achieving a viral cure. That's the finding of a study published in the June 23rd issue of the New England Journal of Medicine.

23 Jun 2011

Telaprevir drug shows promise in curing hepatitis C infection

The drug telaprevir (Incivek) provides a dramatic improvement in the treatment of the most common form of hepatitis C infection, says an international team of investigators led by Dr. Ira M. Jacobson of NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

23 Jun 2011

Nontoxic gold nanoparticles could detect growth of early tumors in liver

Hepatocellular carcinoma is the most common cancer to strike the liver. More than 500,000 people worldwide, concentrated in sub-Saharan Africa and Southeast Asia, are diagnosed with it yearly. Most of those afflicted die within six months.

23 Jun 2011

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

Pharmasset, Inc. announces that the United States Patent and Trademark Office has issued U.S. patent 7,964,580 titled "Nucleoside Phosphoramidate Prodrugs".

22 Jun 2011

Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase Ib clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus (HCV) infection.

22 Jun 2011

CDT biomarker poor, inaccurate method for detecting unhealthy drinking in HIV-infected adults

Researchers from Boston University School of Medicine (BUSM) have found that among HIV-infected adults with alcohol problems, measuring their carbohydrate-deficient transferrin (CDT) biomarker was a poor and inaccurate method for detecting unhealthy drinking.

21 Jun 2011

Study sheds new light on body's immune response to hepatitis A, C viruses

A surprising finding in a study comparing hepatitis C virus (HCV) with hepatitis A virus (HAV) infections in chimpanzees by a team that includes scientists from the Texas Biomedical Research Institute sheds new light on the nature of the body's immune response to these viruses.

21 Jun 2011

NanoViricides plans to lease new cGMP manufacturing and lab space

NanoViricides, Inc. announced today that it will be leasing new space for cGMP production of its nanoviricides drug candidates against various viral diseases.

20 Jun 2011

Australians getting fatter but living longer and smoking less: Health report card

Experts formulating a report on Australia’s health related figures say that Australian men and women are living longer than ever thanks to a drop in deaths from notorious diseases and cancer, but the rising weight has left the door open to a host of new health problems. The key finding of a major study released today was that excess weight carried by one in four children and more than 60 per cent of adults was contributing to an increase in chronic diseases across the country.

19 Jun 2011

FDA approves NULOJIX

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

18 Jun 2011

Liver stiffness measurement could replace liver biopsy for evaluation of hepatitis C

Non-invasive tests for liver fibrosis, such as liver stiffness measurement or the FibroTest, can predict survival of patients with chronic hepatitis C, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

15 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

MinuteClinic, OhioHealth enter affiliation to enhance high quality care services

MinuteClinic, the retail health care division of CVS Caremark, and OhioHealth, a nationally recognized not-for-profit, charitable health care organization based in Columbus, Ohio, have entered into a clinical affiliation that will enhance the high quality, affordable health care services they provide in central Ohio.

13 Jun 2011

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF).

10 Jun 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Accelerated hepatitis B vaccination schedule effective for high-risk pregnant women

Australian Nobel Prize winner closer to delivering vaccines in food after positive first study in humans

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Daewoong, Medivir sign distribution agreement for Xerclear in China and Hong Kong

Incivek-combination therapy increases chances of HCV patients achieving viral cure

Telaprevir drug shows promise in curing hepatitis C infection

Nontoxic gold nanoparticles could detect growth of early tumors in liver

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C

CDT biomarker poor, inaccurate method for detecting unhealthy drinking in HIV-infected adults

Study sheds new light on body's immune response to hepatitis A, C viruses

NanoViricides plans to lease new cGMP manufacturing and lab space

Australians getting fatter but living longer and smoking less: Health report card

FDA approves NULOJIX

Liver stiffness measurement could replace liver biopsy for evaluation of hepatitis C

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

MinuteClinic, OhioHealth enter affiliation to enhance high quality care services

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in